Dynavax Announces Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Dynavax (DVAX) Tops Q4 EPS by 10c
February 25, 2021 5:27 PM ESTDynavax (NASDAQ: DVAX) reported Q4 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $19.55 million versus the consensus estimate of $13.06 million.
"2020 was an important year for Dynavax as we continue to build a leading vaccine company underpinned... More
